ModernMedicine Resource Center More Topics

Video

Comprehensive care program does not cut COPD hospitalizations

A trial program of patient education/planning aimed at treating exacerbations of COPD early and reducing hospitalization rates proved ineffective.

Chronic Obstructive Pulmonary Disorder

Study finds hike in pneumonia for COPD patients receiving corticosteroidsComorbid CVD is an independent risk factor for CAP in patients with COPD. And inhaled steroids may increase CAP risk.
New COPD guidelines tout bronchodilators and antibioticsUse inhaled corticosteroids sparingly and only in these circumstances in patients with COPD. Details here.
Two tools could help identify undiagnosed significant COPDThe CAPTURE questionnaire along with a peak flow test could assist primary care physicians with severe COPD diagnosis.
No link between long-term oxygen, improved mortality for stable COPDPatients with stable COPD already using supplemental oxygen should discuss continued use with their physician.
A Triple Hitter in One Blast: COPD Lessons from TRILOGYPatients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events
Long-term safety of glycopyrrolate: A randomized study of COPD patientsGlycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
Dual therapy strategies for COPD: The scientific rationale for LAMA & LABAThere is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
Efficacy and safety of LABA/LAMA combinations in COPD: A network meta-analysisUpdate: LABA/LAMA combo therapies
The GOLD guidelines and COPD treatmentThe results of a study indicated that only 36% of COPD patients were prescribed treatment according to the GOLD guidelines. The patients that were on GOLD-recommended pharmacological therapy had a moderate improvement in symptoms and health resource utilization.